ArticleJournal of medical virology2026
Development of a Reverse Transcription Recombinase Polymerase Amplification CRISPR/Cas12a Assay for Visual and Highly Specific Identification of Zika Virus.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Development of a Reverse Transcription Recombinase Polymerase Amplification CRISPR/Cas12a Assay for Visual and Highly Specific Identification of Zika Virus.Journal of medical virology · 2026Article
- The CRISPR-Cas toolkit for mosquito-borne virus surveillance: detection, tracing, and discovery.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Zika virus (ZIKV), a single-stranded positive-sense RNA virus of the Flaviviridae family (Flavivirus genus), causes acute febrile illness and severe congenital anomalies. Serological cross-reactivity with Dengue virus (DENV) and Chikungunya virus (CHIKV) complicates diagnosis, underscoring the urgency of developing specific point-of-care tests for early detection, outbreak mitigation, and reduced misdiagnosis risks. This study established and optimized an RPA-CRISPR/Cas12a assay for the rapid, visual, and highly specific detection of ZIKV. Primers and crRNAs targeting the highly conserved capsid (C) gene were designed, and the assay was systematically evaluated for its specificity, sensitivity, reproducibility, and clinical applicability. The RPA-CRISPR/Cas12a assay enabled naked-eye detection under UV light within 35 min. It demonstrated single-copy sensitivity (1 copy/μL), no cross-reactivity with DENV 1-4, CHIKV, or Japanese encephalitis virus (JEV), and 100% concordance with RT-qPCR in clinical validation. Repeatability tests showed low variability (coefficient of variation (C.V.) < 15%), confirming robust reproducibility. This instrument-free platform integrates rapid visual detection, single-copy sensitivity, high specificity, and field-deployable features, making it particularly suitable for point-of-care testing (POCT) in resource-limited settings. The developed assay provides critical support for early outbreak containment and prenatal screening in ZIKV-endemic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.